Armand de Gramont

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study

Thierry André, Armand de Gramont, Déwi Vernerey et al. · Journal of Clinical Oncology · 2015 · 658 citations

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

Thierry André, Christophe Tournigand, Olivier Rosmorduc et al. · Annals of Oncology · 2004 · 381 citations

Gastrointestinal Oncology, Medicine, Biliary Cancer +6

Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer

Sheela Rao, David Cunningham, Armand de Gramont et al. · Journal of Clinical Oncology · 2004 · 236 citations · Full text

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis

Lucile Astorgues‐Xerri, María E. Riveiro, Annemilaï Tijeras‐Raballand et al. · European Journal of Cancer · 2014 · 133 citations · Full text

Tumor Biology, Selective Small-molecule Inhibitor, Cancer Cell Proliferation +10

Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years

Armand de Gramont, C. Boni, Matilde Navarro et al. · Journal of Clinical Oncology · 2007 · 129 citations

Surgical Oncology, Folfox4 Regimen, Cancer Management +16